TY - JOUR T1 - Non-muscle Invasive Bladder Cancer Molecular Subtypes Predict Differential Response to Intravesical Bacillus Calmette-Guérin JF - medRxiv DO - 10.1101/2021.11.30.21266988 SP - 2021.11.30.21266988 AU - Florus C. de Jong AU - Teemu D. Laajala AU - Robert F. Hoedemaeker AU - Kimberley R. Jordan AU - Angelique C.J. van der Made AU - Egbert R. Boevé AU - Deric K.E. van der Schoot AU - Bart Nieuwkamer AU - Emiel A.M. Janssen AU - Tokameh Mahmoudi AU - Joost L. Boormans AU - Dan Theodorescu AU - James C. Costello AU - Tahlita C.M. Zuiverloon Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/05/2021.11.30.21266988.abstract N2 - The recommended treatment for patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) bladder instillations. However, only 50% of patients benefit from this therapy. In case of progression to advanced disease, patients must undergo a radical cystectomy with significant morbidity and have a poor clinical outcome. Identifying tumors least likely to respond to BCG can translate into alternative treatments, such as early radical cystectomy or novel targeted or immunotherapies. Here we present molecular profiling of 132 BCG-naive, HR-NMIBC patients, and 44 post-BCG recurrences (34 matched), which uncovered three distinct BCG Response Subtypes (BRS1-3). Patients with BRS3 tumors have reduced recurrence and progression-free survival compared to BRS1-2. BRS3 tumors expressed high EMT-basal markers and had an immunosuppresive profile, which was confirmed with spatial proteomics. Tumors which recurred post-BCG were enriched for BRS3. BRS stratification was validated in a second cohort of 151 BCG-naive HR-NMIBC patients and the molecular subtypes outperformed guideline recommended risk stratification based on clinicopathological variables. For clinical application, we validated that a commercially approved assay was able to accurately predict BRS3 tumors (AUROC 0.86). Our findings provide a potential clinical tool for improved identification of HR-NMIBC patients at the highest risk of progression, which can be used to select patients for early radical cystectomy or novel subtype-directed therapies.One Sentence Summary Molecular subtypes are predictive of response to intravesical Bacillus Calmette-Guérin immunotherapy in non-muscle invasive bladder cancer.Competing Interest StatementJ.C.C is co-founder of PrecisionProfile. All other contributing authors have no conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter in the manuscript.Funding StatementThis work was generously supported by MRACE Grant no.107477 (TZ), the Anschutz Foundation (JCC, DT), FICAN Cancer Researcher by the Finnish Cancer Institute (TDL), and in part from CA075115 (DT).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was obtained from the Erasmus MC Medical Research Committee (MEC-2018-1097).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/CostelloLab/BRSpred. https://github.com/CostelloLab/BRSpred https://www.synapse.org/BRSpred BCbladder cancerBCGBacillus Calmette-Guérin BRSBCG response subtypes CIScarcinoma in situ ECMextracellular matrix EMTepithelial-to-mesenchymal transition HR-NMIBChigh-risk non-muscle invasive bladder cancer HGhigh-grade HRhigh-risk HHRvery high-risk LVIlymphovascular invasion MIBCmuscle invasive bladder cancer NMIBCnon-muscle invasive bladder cancer PFSprogression-free survival re-TURBTrepeat transurethral resection of the bladder tumor RFSrecurrence-free survival RCradical cystectomy TAMtumor associated macrophages TMEtumor microenvironment TURBTtransurethral resection of the bladder tumor VHvariant histology ER -